<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02325973</url>
  </required_header>
  <id_info>
    <org_study_id>CV-12-018-IT-PW</org_study_id>
    <nct_id>NCT02325973</nct_id>
  </id_info>
  <brief_title>Assessing Microvascular Resistance Via IMR To Predict Cumulative Outcome in STEMI Patients Undergoing Primary PCI</brief_title>
  <acronym>AMICRO</acronym>
  <official_title>Assessing Microvascular Resistance Via IMR To Predict Cumulative Outcome in STEMI Patients Undergoing Primary PCI (AMICRO)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Jude Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Jude Medical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess whether the Index of Microcirculatory Resistance (IMR)
      can be considered a prognostic predictor for the occurrence of events at one year of follow
      up after primary Percutaneous Coronary Intervention (PCI) in ST-Elevation Myocardial
      Infarction (STEMI) patients.

      Any correlation between IMR and the short and medium term outcomes, defined as cardiovascular
      death, re-Myocardial Infarct (MI), re-hospitalization for Heart Failure (HF), resuscitation
      or Implantable Cardioverter Defibrillator (ICD) appropriate shock, will be assessed in the
      study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective, multicentre study designed to evaluate IMR ability to predict events occurrence,
      defined as Cardiovascular death, re-MI, re-hospitalization for HF, resuscitation or ICD
      appropriate shock, during a 1 year follow-up period.

      All participants will have the culprit lesion treated following clinical practice and
      guidelines; Fractional Flow Reserve (FFR) and IMR will be measured after the primary PCI
      procedure to evaluate treatment success and myocardial viability. Non-culprit lesions will be
      functionally evaluated through FFR index and will be treated if FFR will show functional
      stenosis. FFR and IMR will be measured to evaluate treatment success and myocardial
      viability. Patients will be followed-up at 1m, 6m and 1y periods.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite of: cardiovascular death*, re-myocardial infarct, re-hospitalization for heart failure (HF) and Congestive Heart Failure (CHF), resuscitation or ICD appropriate shock.</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>New CHF during index hospitalization</measure>
    <time_frame>At the end of hospital stay, an expected average of 5-10 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left Ventricular (LV) remodeling</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for new revascularization (revascularization yes/no)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent thrombosis (thrombosis yes/no)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ST resolution or residual ST elevation post PCI (Electrocardiographic ST-segment elevation in two or more contiguous electrocardiogram (ECG) leads)</measure>
    <time_frame>At the end of hospital stay, an expected average of 5-10 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">242</enrollment>
  <condition>Multi Vessel Coronary Artery Disease</condition>
  <condition>STEMI</condition>
  <arm_group>
    <arm_group_label>IMR evaluation</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Assessment of IMR index in coronaries through PressureWire Certus guidewire</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PressureWire Certus guidewire</intervention_name>
    <description>Assessment of IMR index in coronaries through PressureWire Certus guidewire</description>
    <arm_group_label>IMR evaluation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient of legal age in hosting country able and willing to provide informed consent
             form

          2. Hospital admission either within 12 h of symptom onset or between 12 and 24 h after
             onset with evidence of continuing ischemia

          3. Electrocardiographic ST-segment elevation â‰¥1 mm in two or more contiguous ECG leads,
             or with a left bundle-branch block (LBBB)

          4. Multivessel diseased patients with lesions in the proximal 2/3 part of the vessels

          5. Culprit Lesion EyeBall (EB) identified during evaluation of basal angiography

          6. Presence of at least one non-culprit lesion &gt;50% EB detected in the basal angiography
             and eligible for PCI for which the operators decision is to perform a staged
             pre-discharge angioplasty procedure

        Exclusion Criteria:

          1. Patients who cannot give informed consent

          2. A life expectancy of less than 1 year

          3. Patients who are pregnant or nursing

          4. Contra-indication to angiography

          5. Allergy/intolerance to Adenosine

          6. Contra-indication/Allergy/Intolerance to contrast media or to medical therapy foreseen
             for PCI

          7. Documented allergy to Adenosine diphosphate (ADP) inhibitors (aspirin and clopidogrel)

          8. New infarct on the same area of a previous infarct

          9. Critical non treatable Lesion EB&gt;70% downstream of the culprit lesion

         10. Absence of non-culprit lesion/s

         11. Patient with hemodynamic instability not controllable with medical therapy and/or need
             intra aortic balloon pump implantation (IABP)

         12. Prior Coronary Artery Bypass Graft (CABG) or indication for CABG

         13. Patients with Left Main (LM) coronary artery disease requiring revascularization
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Massimo Fineschi, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Policlinico Le Scotte, Siena</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marco Valgimigli, MD</last_name>
    <role>Study Chair</role>
  </overall_official>
  <overall_contact>
    <last_name>Massimo Scandella</last_name>
    <phone>+393357297716</phone>
    <email>mscandella@sjm.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alessandra Denaro</last_name>
    <phone>+393427528882</phone>
    <email>adenaro@sjm.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ospedale Giovanni Paolo II</name>
      <address>
        <city>Sciacca</city>
        <state>Agrigento</state>
        <zip>92019</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giuseppe Mezzapelle, MD</last_name>
      <phone>+390925962296</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Generale Regionale &quot;F. Miulli&quot;</name>
      <address>
        <city>Acquaviva delle Fonti</city>
        <state>BA</state>
        <zip>70021</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katya Lucarelli, MD</last_name>
      <phone>+390803054115</phone>
    </contact>
    <investigator>
      <last_name>Katya Lucarelli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Careggi</name>
      <address>
        <city>Firenze</city>
        <state>FI</state>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>David Antoniucci, MD</last_name>
      <phone>+390557947966</phone>
    </contact>
    <investigator>
      <last_name>David Antoniucci, PROF</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Villa Scassi</name>
      <address>
        <city>Genova</city>
        <state>GE</state>
        <zip>16149</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paolo Rubartelli, MD</last_name>
      <phone>+390108492349</phone>
    </contact>
    <investigator>
      <last_name>Paolo Rubartelli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione Toscana G.Monasterio - Ospedale del Cuore</name>
      <address>
        <city>Massa</city>
        <state>MS</state>
        <zip>54100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sergio Berti, MD</last_name>
      <phone>+390585493634</phone>
    </contact>
    <investigator>
      <last_name>Sergio Berti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera di Padova</name>
      <address>
        <city>Padova</city>
        <state>PD</state>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giuseppe Tarantini, PROF</last_name>
      <phone>+390498212311</phone>
    </contact>
    <investigator>
      <last_name>Giuseppe Tarantini, PROF</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Ospedali Riuniti Marche Nord</name>
      <address>
        <city>Pesaro</city>
        <state>PU</state>
        <zip>61121</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lucia Uguccioni, MD</last_name>
      <phone>+390721362244</phone>
    </contact>
    <investigator>
      <last_name>Lucia Uguccioni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Policlinico S.Matteo</name>
      <address>
        <city>Pavia</city>
        <state>PV</state>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maurizio Ferrario, MD</last_name>
      <phone>+390382501598</phone>
    </contact>
    <investigator>
      <last_name>Maurizio Ferrario, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arcispedale Santa Maria Nuova</name>
      <address>
        <city>Reggio Emilia</city>
        <state>RE</state>
        <zip>43123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Manari, MD</last_name>
      <phone>+390522296595</phone>
    </contact>
    <investigator>
      <last_name>Antonio Manari, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale di Castelfranco Veneto</name>
      <address>
        <city>Castelfranco Veneto</city>
        <state>Treviso</state>
        <zip>31033</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carlo Cernetti, MD</last_name>
      <phone>+390423731900</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Presidio Ospedaliero di Conegliano</name>
      <address>
        <city>Conegliano</city>
        <state>Treviso</state>
        <zip>31015</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giovanni Turiano, MD</last_name>
      <phone>+390438 663613</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale di Circolo Fondazione Macchi</name>
      <address>
        <city>Varese</city>
        <state>VA</state>
        <zip>21100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edoardo Verna, MD</last_name>
      <phone>+390332278645</phone>
    </contact>
    <investigator>
      <last_name>Edoardo Verna, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Sant'Andrea</name>
      <address>
        <city>La Spezia</city>
        <zip>19100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gianfranco Mazzotta, MD</last_name>
      <phone>+390187533459</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Policlinico Le Scotte</name>
      <address>
        <city>Siena</city>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Massimo Fineschi</last_name>
      <email>orfine@tin.it</email>
    </contact>
    <investigator>
      <last_name>Massimo Fineschi, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 30, 2014</study_first_submitted>
  <study_first_submitted_qc>December 19, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 25, 2014</study_first_posted>
  <last_update_submitted>October 21, 2016</last_update_submitted>
  <last_update_submitted_qc>October 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 24, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>STEMI</keyword>
  <keyword>IMR</keyword>
  <keyword>FFR</keyword>
  <keyword>microcirculatory</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

